MBX Biosciences, a Phase 2 biotech developing precision peptides for endocrine and metabolic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Co-founder led MBX Biosciences is developing peptides that are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its lead candidate, MBX 2109, is a parathyroid hormone peptide that is designed as a potential long-acting hormone replacement therapy for chronic hypoparathyroidism. The company dosed its first patient for its Phase 2 trial in August 2024.
The Carmel, IN-based company was founded in 2018 and plans to list on the Nasdaq under the symbol MBX. MBX Biosciences filed confidentially on March 22, 2024. J.P. Morgan, Jefferies, Stifel, and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
